Zantac Lung Cancer

The heartburn medication Zantac and other ranitidine medications have received some well-deserved negative press lately. The Food and Drug Administration recently withdrew these drugs from the market due to findings that they contain NDMA (N-Nitrosodimethylamine). NDMA is a contaminant that is widely considered (among national and international health organizations) a probable carcinogen or cancer-causing agent. One of the cancers associated with NDMA is lung cancer – even in non-smokers.

Zantac

Zantac is the popular and profitable name-brand version of ranitidine, which is used to treat the following health conditions:

• Heartburn
• Gastroesophageal reflux disease (GERD)
• Ulcers
• Other related health issues

If you regularly used Zantac to treat your condition, are a non-smoker, and have been diagnosed with lung cancer, there may be a connection, and you may have a strong legal case.

The NDMA Connection

NDMA was initially identified in Zantac in the spring of 2019 when an online pharmacy was performing routine quality assurance testing in its efforts to ensure the safety of the drugs it distributes. Several of the manufacturers of similar ranitidine products quickly halted production and removed their drugs from the shelves. Further, several large drugstore chains pulled the medication from their stores. The FDA, however, took an additional several months before halting the sale of Zantac and similar medications. A wide range of well-respected clinical studies and research finds a connection between NDMA and lung cancer – even in non-smokers.

Call an Experienced Drug Injury Lawyer Today

If you’re a non-smoker who regularly took Zantac and who has been diagnosed with lung cancer, don’t delay consulting with a dedicated drug injury lawyer. You may be entitled to compensation.